2. SYSTEMATIC REVIEW OF THE PREVALENCE OF DRUG INTERACTIONS IN HOSPITAL SETTINGS FOR THE PERIOD OF 2022-2023
Main Article Content
Abstract
Objective: The systematic review aims to identify common pairs of adverse drug-drug interactions (DDIs) in hospital treatment based on published research findings worldwide from 2022 to 2023.
Materials and methods: Utilize specific command syntax to search and filter on PubMed for full-text studies in English that focus on the DDI rates, published during the period 2022-2023.
Results: A total of 393 different DDI pairs were recorded from 20 articles that met the study inclusion criteria. The most frequent DDI pair was lorazepam + olanzapine (55.5%). Ritonavir was the most frequently implicated drug, involved in 24 out of 393 DDI pairs (6.1%). Eleven DDI pairs were listed in the "Issuance of the list of contraindicated drug interactions in clinical practice at healthcare facilities" (Decision No. 5948/QD-BYT). Among these, erythromycin + fluconazole and ceftriaxone + calcium gluconate were the most commonly prescribed, with the rates of 33.6% and 25.0%, respectively.
Conclusions: The prescription of interacting drugs remains a critical concern in clinical practice. Many DDI pairs observed in hospitals worldwide are not included in Decision No. 5948/QD- BYT (2021). Therefore, healthcare professionals need to regularly update their knowledge of drug interations from various sources to optimize decision-making for the prevention and resolution of DDIs, thereby ensuring patient safety during treatment.
Article Details
Keywords
Drug-drug interactions, Decision No. 5948/QD-BYT, systematic review, Lexicomp.
References
[2] Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. Journal of clin- ical pharmacy and therapeutics. 2008, 33(2): 141- 151.
[3] Perić A, Udilović A, Dobrić S et al., The impact of treatment choices on potential drug-drug in- teractions in hypertensive patients. British jour- nal of clinical pharmacology, 2022, 88(5): 2340 - 2348.
[4] Nguyễn Thị Ngọc Diễm, Phạm Thành Suôl, Nguyễn Thiên Vũ và cộng sự, Tương tác thuốc trong đơn thuốc điều trị ngoại trú-nội trú và yếu tố liên quan tại bệnh viện Trường Đại học Y Dược Cần Thơ năm 2021-2022. Tạp chí Y Dược học Cần Thơ, 2022, 51: 236 – 244.
[5] Roblek T, Vaupotic T, Mrhar A et al., Drug- drug interaction software in clinical practice: A systematic review. European journal of clinical pharmacology, 2015, 71(2): 131 - 142.
[6] Bộ Y tế, Quyết định số 5948/QĐ-BYT. Quyết định về việc ban hành danh mục tương tác thuốc chống chỉ định trong thực hành lâm sàng tại các cơ sở khám bệnh, chữa bệnh, 2021: 2-3.
[7] Liu Y, Yang M, Ding Y et al., Clinical signifi- cance of potential drug-drug interactions in older adults with psychiatric disorders: A retrospective study. BMC psychiatry, 2022, 22(1): 563.
[8] Mills KT, Stefanescu A, He J, The global epi- demiology of hypertension. Nature reviews Ne- phrology, 2020, 16(4): 223 - 237.
[9] Li T, Hu B, Ye L et al., Clinically Significant Cytochrome P450-Mediated Drug-Drug Inter- actions in Children Admitted to Intensive Care Units. International journal of clinical practice, 2022, 2786914.
[10] Nawaz HA, Khan TM, Adil Q et al., A Prospec- tive Study of Medication Surveillance of a Pedi- atric Tertiary Care Hospital in Lahore, Pakistan. Pediatric reports, 2022, 14(2): 312 - 319.